Dr. Reddy's Laboratories Ltd. NSE: DRREDDY | BSE: 500124

Turnaround Potential

In 4 Starfolio Baskets

Download real time

1280.00 4.80 (0.38%)

25.49% Gain from 52W Low

5.1M

NSE+BSE Volume

High volume today

NSE 03 Dec, 2025 3:29 PM (IST)

HC Ruling

Delhi HC reportedly allows Dr Reddy's to manufacture and export its weight-loss drug, Semaglutide See details

Dr. Reddy's Labs News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Dr. Reddy's Labs from all sources in a single place.

Dr. Reddy's Laboratories Ltd.

02 Dec 2025, 10:06PM

1280.00

0.38%

Dr Reddy's unit Aurigene Oncology gets encouraging early results in Phase 1 trial of new cancer drug

Business Line

The early data indicate an overall response rate of 63.6% in efficacy-evaluable patients and 58.3% in the intent-to-treat group.

Number of FII/FPI investors decreased from 917 to 872 in Sep 2025 qtr

Dr. Reddy's Laboratories Ltd.

02 Dec 2025, 02:36PM

1280.00

0.38%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Intimation of Analyst meet

Dr. Reddy's Laboratories Ltd.

28 Nov 2025

1280.00

0.38%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Analyst meet intimation

Dr. Reddy's Laboratories Ltd.

26 Nov 2025

1280.00

0.38%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Ltd.

26 Nov 2025

1280.00

0.38%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Ltd.

25 Nov 2025

1280.00

0.38%

Dr. Reddy's Laboratories shares jump over 1% as European Commission approves biosimilar AVT03

Economic Times

Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone complications. This significant milestone, following a positive CHMP recommendation, allows marketing across EU member states and EEA countries. Dr. Reddy's, in partnership with Alvotech, will commercialize the drug under brands Acyvbra and Xbonzy.

Dr. Reddy's Laboratories Ltd. is trading at high day volume of 5.0M.

Dr Reddy's gets marketing authorisation for biosimilar fromEuropean Commission

Business Line | 24 Nov 2025

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1280.00

0.38%

Policymakers-industry partnership vital for healthcare delivery: Dr Reddy's

Business Standard

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1280.00

0.38%

Dr Reddy's Gets European Nod For Biosimilar To Treat Osteoporosis

NDTV Profit

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Nov 2025

1280.00

0.38%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Announcement under Regulation 30 of SEBI (LODR) Regulations, 2015 - Press Release

Dr. Reddy's Laboratories Ltd.

18 Nov 2025

1280.00

0.38%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Intimation of Analyst meet

Is Dr. Reddy's Laboratories Ltd. worth buying?

538 Votes:

Buy 77.88%

Sell 12.64%

Hold 9.48%

RESEARCH REPORTS

Sell SEE REPORTS >

Hold SEE REPORTS >